Primary tumors are responsible for 10% of cancer deaths. In most cases, the main cause of
mortality is the formation of metastases. Accumulating evidence suggests that a …

Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …

Background DNA methylation and the Polycomb repression system are epigenetic
mechanisms that play important roles in maintaining transcriptional repression. Recent …

Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …

Background Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible
global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin …

Inflammatory signaling is required for hematopoietic stem and progenitor cell (HSPC)
development. Here, we studied the involvement of RIG-I-like receptors (RLRs) in HSPC …

Higher-risk myelodysplastic syndromes (MDS) are defined by patients who fall into higher-
risk group categories in the original or revised International Prognostic Scoring System …

Clinical experience with 5-azacytidine and decitabine treatment of myelodysplastic
syndromes (MDS), complemented by biological and pharmacological studies, has revealed …

BACKGROUND. Mutational inactivation in cancer of key apoptotic pathway components,
such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis …

The deoxycytidine analog decitabine (DAC) can deplete DNA methyl-transferase 1 (DNMT1)
and thereby modify cellular epigenetics, gene expression, and differentiation. However, a …